- Home
Clinical trials

Search for a clinical trial
Filter
Filter
Geographical location
Type of cancer
Refine your search
Age
Phase
Search for a clinical trial
192 result(s)
- SarcomasParisADCT-601-102A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.
SARAH WATSON
- Lung cancerParisAK112-301-HARMONiA randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.
NICOLAS GIRARD
- Breast cancerParis, Saint-CloudALCINA-2Analysis of Circulating Tumor Markers in Blood
FRANCOIS-CLEMENT BIDARD
- Lung cancerParisBGB-LC-201A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.
NICOLAS GIRARD
- Lung cancerParisBI1438-0009 (DAREON 9)DAREONTM-9: A Phase Ib open-label dose escalation and dose;confirmation safety study of intravenous BI 764532 in;combination with topotecan for the treatment of patients with;small cell lung cancer
PAULINE DU RUSQUEC
- Lung cancerParisBRIDGE (D9106C00002)A multicentre, Phase II, single-arm, interventional study of;neoadjuvant durvalumab and platinum-based chemotherapy;(CT), followed by either surgery and adjuvant durvalumab or;chemoradiotherapy (CRT) and consolidation durvalumab, in;participants with resectable or borderline resectable stage;IIB-IIIB Non-small Cell Lung Cancer (NSCLC)
NICOLAS GIRARD
- Lung cancerParisCOCOONA Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard;dermatologic management on selected dermatologic adverse events among patients with locally;advanced or metastatic EGFR-mutated NSCLC treated first-line with;amivantamab + lazertinib.
ELISA GOBBINI
- Lung cancerParisENCO-BRAF (IFCT-1904)A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
CLEMENCE BASSE
- Breast cancerSaint-CloudFAP-IT68Ga-FAPI-46 PET/CT for predicting histological response;to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.
- ParisGCT1047-01First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors.
CHRISTOPHE LE TOURNEAU
- Childhood and adolescent cancersParisGSK213406A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours
FRANCOIS DOZ
- ENT/Head and Neck CancersParisHPV.DCVaxMulticentric randomized phase I/IIa trial of the safety and immunogenicity of a;therapeutic anti-HPV DC targeting vaccine in patients with Human papillomavirus;(HPV)-positive oropharyngeal cancer.
CHRISTOPHE LE TOURNEAU
- Paris, Saint-CloudLE DECLIC-EPRI (IC 2019-06)DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI.
EVELYNE RENAULT TESSIER
- Childhood and adolescent cancersParisLYNPARZA (D0816C000025)A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety;and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with;Solid Tumours
ISABELLE AERTS GAJDOS
- Bladder cancerParisMK3475-992A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to;Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With;Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder;Cancer (MIBC) (KEYNOTE-992)
GILLES CREHANGE
- ENT/Head and Neck CancersParisMK7902-009 (LEAP-009)Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
CHRISTOPHE LE TOURNEAU
- Breast cancerParis, Saint-CloudMONDRIANChemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study
FRANCOIS-CLEMENT BIDARD
- Childhood and adolescent cancersParisMS100070-0087Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors.
FRANCOIS DOZ
- ENT/Head and Neck CancersParis, Saint-CloudNIVOPOST-OP / GORTEC 2018-01A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)
CHRISTOPHE LE TOURNEAU, LAURENCE BOZEC
- Prostate cancerParisPRESTO (GETUG-AFU 36)Prostate-cancer treatment using stereotactic radiotherapy for oligometastases;ablation in hormone-sensitive patients À a GETUG-AFU phase III randomized controlled trial
GILLES CREHANGE
- Lung cancerParis, Saint-CloudREAL MOOV LUNGReal Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG
NICOLAS GIRARD
- Breast cancerParis, Saint-CloudROMANCE (RAD05-UC-0107/1803)Prospective study of omission of whole-breast radiotherapy following breast-conserving surgery in patients with very low risk ductal carcinoma in situ of the breast
- ParisDF1001-001A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
EMANUELA ROMANO
- ParisMK3475-522 (Keynote-522)A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
MARIE PAULE SABLIN
- ParisGSK 219451 - POPSTARPhase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR).
AMAURY LERUSTE
- Paris, Saint-CloudREVCCIUse of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally Implanted Venous Access Device (IVAD) for Chemotherapy Under Local Anesthesia
ABDELMALEK GHIMOUZ
- Childhood and adolescent cancersParis I3Y-MC-JPEHA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
ISABELLE AERTS GAJDOS
- ENT/Head and Neck CancersParis219885 GALAXIES H&N-202A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
CHRISTOPHE LE TOURNEAU
- Colorectal cancerSaint-CloudADAGE - Prodige 34Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.
- Cancers gynécologiquesSaint-CloudAFTERGYNOptimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase (AFTERGYN)
DIANA BELLO ROUFAI